It recorded a net loss of $895,375.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
May 31, 2026
|
FY 2025
May 31, 2025
|
FY 2024
May 31, 2024
|
FY 2023
May 31, 2023
|
FY 2022
May 31, 2022
|
FY 2021
May 31, 2021
|
FY 2020
May 31, 2020
|
FY 2019
May 31, 2019
|
FY 2018
May 31, 2018
|
FY 2017
May 31, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
0
|
—
|
—
|
—
|
0
|
—
|
—
|
0
|
| Cost of revenue |
—
|
—
|
—
|
—
|
0
-37.3%
|
0
-68.3%
|
0
|
—
|
—
|
0
-85.7%
|
| Gross profit |
—
|
—
|
0
-100.0%
|
0
-88.0%
|
0
+14.5%
|
0
-95.9%
|
0
|
—
|
—
|
0
-73.4%
|
| Research and development |
—
|
—
|
—
|
0
-40.8%
|
0
-34.4%
|
0
-41.6%
|
0
+50.1%
|
0
-37.4%
|
0
+40.8%
|
0
-54.3%
|
| Selling, general and administrative |
0
+79.2%
|
0
+83.5%
|
0
-57.8%
|
0
-17.6%
|
0
+79.9%
|
0
-53.1%
|
0
+173.6%
|
0
-38.5%
|
0
-41.2%
|
0
+65.6%
|
| Net income |
-1
-58.1%
|
-1
-297.4%
|
-0
+71.2%
|
-0
+29.0%
|
-1
+23.4%
|
-1
+16.6%
|
-1
-20.6%
|
-1
+41.4%
|
-2
-23.8%
|
-1
|
| Basic EPS |
-0.04
-33.3%
|
-0.03
-200.0%
|
-0.01
+0.0%
|
-0.01
+0.0%
|
-0.01
|
—
|
—
|
—
|
—
|
—
|
| Weighted average shares, basic |
21
+4.6%
|
20
+84.9%
|
11
-82.9%
|
63
+0.2%
|
63
|
—
|
—
|
—
|
—
|
—
|
| Other measures | ||||||||||
| Depreciation and amortization |
—
|
—
|
—
|
0
|
—
|
0
+31.9%
|
0
+218.3%
|
0
-99.5%
|
0
|
—
|
| Margins | ||||||||||
| Gross margin |
—
|
—
|
—
|
—
|
—
|
—
|
89.32%
|
—
|
—
|
34.87%
|
| Profit margin |
—
|
—
|
—
|
—
|
—
|
—
|
-1,140.32%
|
—
|
—
|
-20,087.56%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- STME (OTC)
- Fiscal year ends
- May 31
- Incorporated in
- NV
- Headquarters
- Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1493712
- Former names
- Cell MedX Corp. (until Oct 15, 2024); Sports Asylum, Inc. (until Oct 9, 2014); Plandel Resources, Inc. (until Mar 24, 2014)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.